Net Income (Loss) Attributable to Parent in USD of LIGAND PHARMACEUTICALS INC from Q2 2010 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary: LIGAND PHARMACEUTICALS INC quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
LIGAND PHARMACEUTICALS INC Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $117M.
LIGAND PHARMACEUTICALS INC Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $48.6M, a 7.38% increase year-over-year.
LIGAND PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2024 was -$4.03M, a 108% decline from 2023.
LIGAND PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2023 was $52.2M.
LIGAND PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2022 was -$33.4M, a 158% decline from 2021.

Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)

Net Income (Loss) Attributable to Parent, Quarterly (USD)

Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)

Net Income (Loss) Attributable to Parent, Annual (USD)

Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

LIGAND PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2025	$48.6M	$117M	+$124M		01 Jul 2025	30 Sep 2025	10-Q	07 Nov 2025
Q2 2025	-$75.9M	$4.85M	+$56.8M		01 Apr 2025	30 Jun 2025	10-Q	08 Aug 2025
Q1 2025	-$133M	-$42.5M	-$129M	-149%	01 Jan 2025	31 Mar 2025	10-Q	08 Aug 2025
Q4 2024	-$4.03M	-$31.1M	-$49.3M	-271%	01 Oct 2024	31 Dec 2024	10-K	28 Feb 2025
Q3 2024	$45.2M	-$7.17M	+$3.1M	+30.2%	01 Jul 2024	30 Sep 2024	10-Q	07 Nov 2025
Q2 2024	$42.1M	-$51.9M	-$54.2M	-2367%	01 Apr 2024	30 Jun 2024	10-Q	07 Nov 2025
Q1 2024	$96.3M	$86.1M	+$44.2M	+105%	01 Jan 2024	31 Mar 2024	10-Q	07 Nov 2025
Q4 2023	$52.2M	$18.2M	+$35.7M		01 Oct 2023	31 Dec 2023	10-K	28 Feb 2025
Q3 2023	$16.5M	-$10.3M	-$10.7M	-2643%	01 Jul 2023	30 Sep 2023	10-Q	08 Nov 2024
Q2 2023	$27.2M	$2.29M	+$3.19M		01 Apr 2023	30 Jun 2023	10-Q	08 Nov 2024
Q1 2023	$24M	$41.9M	+$57.3M		01 Jan 2023	31 Mar 2023	10-Q	08 Nov 2024
Q4 2022	-$33.4M	-$17.5M	-$12.1M	-223%	01 Oct 2022	31 Dec 2022	10-K	28 Feb 2023
Q3 2022	-$21.3M	$404K	-$13.3M	-97.1%	01 Jul 2022	30 Sep 2022	10-Q	09 Nov 2023
Q2 2022	-$7.97M	-$895K	-$31.6M	-103%	01 Apr 2022	30 Jun 2022	10-Q	09 Nov 2023
Q1 2022	$23.6M	-$15.4M	-$33.5M	-185%	01 Jan 2022	31 Mar 2022	10-Q	09 Nov 2023
Q4 2021	$57.1M	-$5.42M	-$11.2M	-194%	01 Oct 2021	31 Dec 2021	10-K	28 Feb 2023
Q3 2021	$68.3M	$13.7M	+$20.4M		01 Jul 2021	30 Sep 2021	10-K	28 Feb 2023
Q2 2021	$47.9M	$30.7M	+$8.64M	+39.1%	01 Apr 2021	30 Jun 2021	10-K	28 Feb 2023
Q1 2021	$39.3M	$18.1M	+$42.2M		01 Jan 2021	31 Mar 2021	10-K	28 Feb 2023
Q4 2020	-$2.99M	$5.76M	+$13.1M		01 Oct 2020	31 Dec 2020	10-K	24 Feb 2021
Q3 2020	-$16.1M	-$6.7M	+$8.55M	+56.1%	01 Jul 2020	30 Sep 2020	10-Q	09 Nov 2021
Q2 2020	-$24.7M	$22.1M	+$36.5M		01 Apr 2020	30 Jun 2020	10-Q	09 Nov 2021
Q1 2020	-$61.2M	-$24.1M	-$690M	-104%	01 Jan 2020	31 Mar 2020	10-Q	09 Nov 2021
Q4 2019	$629M	-$7.37M	+$35.1M	+82.7%	01 Oct 2019	31 Dec 2019	10-K	24 Feb 2021
Q3 2019	$594M	-$15.3M	-$82.6M	-123%	01 Jul 2019	30 Sep 2019	10-K	24 Feb 2021
Q2 2019	$677M	-$14.4M	-$87.6M	-120%	01 Apr 2019	30 Jun 2019	10-K	24 Feb 2021
Q1 2019	$764M	$666M	+$621M	+1372%	01 Jan 2019	31 Mar 2019	10-K	24 Feb 2021
Q4 2018	$143M	-$42.5M	$0	0%	01 Oct 2018	31 Dec 2018	10-K	27 Feb 2020
Q3 2018	$143M	$67.4M	$0	0%	01 Jul 2018	30 Sep 2018	10-K	27 Feb 2020
Q2 2018	$143M	$73.2M	$0	0%	01 Apr 2018	30 Jun 2018	10-K	27 Feb 2020
Q1 2018	$143M	$45.3M	$0	0%	01 Jan 2018	31 Mar 2018	10-K	27 Feb 2020
Q4 2017	$143M	-$42.5M	-$39.4M	-1259%	01 Oct 2017	31 Dec 2017	10-K	28 Feb 2019
Q3 2017	$183M	$67.4M	+$66.3M	+6309%	01 Jul 2017	30 Sep 2017	10-K	28 Feb 2019
Q2 2017	$116M	$73.2M	+$79.3M		01 Apr 2017	30 Jun 2017	10-K	28 Feb 2019
Q1 2017	$37M	$45.3M	+$38.7M	+585%	01 Jan 2017	31 Mar 2017	10-K	28 Feb 2019
Q4 2016	-$1.64M	-$3.13M	-$9.47M	-149%	01 Oct 2016	31 Dec 2016	10-K	01 Mar 2018
Q3 2016	$7.83M	$1.05M	-$198M	-99.5%	01 Jul 2016	30 Sep 2016	10-K	01 Mar 2018
Q2 2016	$206M	-$6.17M	-$29.7M	-126%	01 Apr 2016	30 Jun 2016	10-K	01 Mar 2018
Q1 2016	$236M	$6.61M	+$5.85M	+776%	01 Jan 2016	31 Mar 2016	10-K	01 Mar 2018
Q4 2015	$230M	$6.34M	-$714K	-10.1%	01 Oct 2015	31 Dec 2015	10-K	28 Feb 2017
Q3 2015	$231M	$199M	+$198M	+15460%	01 Jul 2015	30 Sep 2015	10-K	28 Feb 2017
Q2 2015	$32.7M	$23.6M	+$22M	+1380%	01 Apr 2015	30 Jun 2015	10-K	28 Feb 2017
Q1 2015	$10.7M	$754K	-$1.34M	-64%	01 Jan 2015	31 Mar 2015	10-K	28 Feb 2017
Q4 2014	$12M	$7.06M	+$5.19M	+277%	01 Oct 2014	31 Dec 2014	10-K	14 Nov 2016
Q3 2014	$6.84M	$1.28M	-$685K	-34.9%	01 Jul 2014	30 Sep 2014	10-K	14 Nov 2016
Q2 2014	$7.52M	$1.59M	-$4.5M	-73.9%	01 Apr 2014	30 Jun 2014	10-K	14 Nov 2016
Q1 2014	$12M	$2.1M	+$602K	+40.3%	01 Jan 2014	31 Mar 2014	10-K	14 Nov 2016
Q4 2013	$11.4M	$1.87M	+$806K	+75.8%	01 Oct 2013	31 Dec 2013	10-K	23 Feb 2015
Q3 2013	$10.6M	$1.97M	+$2.16M		01 Jul 2013	30 Sep 2013	10-K	23 Feb 2015
Q2 2013	$8.46M	$6.09M	+$8.62M		01 Apr 2013	30 Jun 2013	10-K	23 Feb 2015
Q1 2013	-$165K	$1.5M	+$362K	+32%	01 Jan 2013	31 Mar 2013	10-K	23 Feb 2015
Q4 2012	-$527K	$1.06M	-$3.63M	-77.3%	01 Oct 2012	31 Dec 2012	10-K/A	12 Dec 2014
Q3 2012	$3.1M	-$194K	+$3.98M	+95.4%	01 Jul 2012	30 Sep 2012	10-K/A	12 Dec 2014
Q2 2012	-$884K	-$2.53M	-$2.11M	-499%	01 Apr 2012	30 Jun 2012	10-K/A	12 Dec 2014
Q1 2012	$1.22M	$1.13M	-$8.49M	-88.2%	01 Jan 2012	31 Mar 2012	10-K/A	12 Dec 2014
Q4 2011	$9.72M	$4.69M			01 Oct 2011	31 Dec 2011	10-K	14 Mar 2013
Q3 2011		-$4.18M	+$7.67M	+64.7%	01 Jul 2011	30 Sep 2011	10-K	14 Mar 2013
Q2 2011		-$422K	-$139K	-49.1%	01 Apr 2011	30 Jun 2011	10-K	14 Mar 2013
Q1 2011		$9.63M			01 Jan 2011	31 Mar 2011	10-K	14 Mar 2013
Q3 2010		-$11.8M			01 Jul 2010	30 Sep 2010	10-Q/A	10 Feb 2012
Q2 2010		-$283K			01 Apr 2010	30 Jun 2010	10-Q/A	10 Feb 2012

LIGAND PHARMACEUTICALS INC Annual Net Income (Loss) Attributable to Parent (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2024	-$4.03M	-$56.2M	-108%	01 Jan 2024	31 Dec 2024	10-K	28 Feb 2025
2023	$52.2M	+$85.5M		01 Jan 2023	31 Dec 2023	10-K	28 Feb 2025
2022	-$33.4M	-$90.5M	-158%	01 Jan 2022	31 Dec 2022	10-K	28 Feb 2025
2021	$57.1M	+$60.1M		01 Jan 2021	31 Dec 2021	10-K	29 Feb 2024
2020	-$2.99M	-$632M	-100%	01 Jan 2020	31 Dec 2020	10-K	28 Feb 2023
2019	$629M	+$486M	+339%	01 Jan 2019	31 Dec 2019	10-K	28 Feb 2022
2018	$143M	+$131M	+1041%	01 Jan 2018	31 Dec 2018	10-K	24 Feb 2021
2017	$12.6M	+$14.2M		01 Jan 2017	31 Dec 2017	10-K	27 Feb 2020
2016	-$1.64M	-$231M	-101%	01 Jan 2016	31 Dec 2016	10-K	28 Feb 2019
2015	$230M	+$218M	+1811%	01 Jan 2015	31 Dec 2015	10-K	01 Mar 2018
2014	$12M	+$604K	+5.29%	01 Jan 2014	31 Dec 2014	10-K	28 Feb 2017
2013	$11.4M	+$11.9M		01 Jan 2013	31 Dec 2013	10-K	14 Nov 2016
2012	-$527K	-$10.2M	-105%	01 Jan 2012	31 Dec 2012	10-K	23 Feb 2015
2011	$9.72M	+$20.1M		01 Jan 2011	31 Dec 2011	10-K/A	12 Dec 2014
2010	-$10.4M			01 Jan 2010	31 Dec 2010	10-K	14 Mar 2013

* An asterisk sign (*) next to the value indicates that the value is likely invalid.